HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $380 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $380.
August 04, 2023 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $380.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Vertex Pharmaceuticals. This could potentially lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100